Spots Global Cancer Trial Database for Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
Official Title: A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Study ID: NCT04277637
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Hematologyoncology, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus, Ohio, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States
Md Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Concord Repatriation General Hospital, Concord, New South Wales, Australia
Orange Health Service (Central West Cancer Care Centre), Orange, New South Wales, Australia
Pindara Private Hospital, Benowa, Queensland, Australia
John Flynn Private Hospital, Tugun, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Flinders Medical Centre, Bedford PK, South Australia, Australia
Box Hill Hospital, Box Hill, Victoria, Australia
Monash Health, Clayton, Victoria, Australia
St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden, Dresden, , Germany
Universitaetsklinikum Ulm, Innere Medizin Iii, Ulm, , Germany
Ospedale San Raffaele, Milano, , Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, , Italy
Azienda Unita Sanitaria Locale Di Ravenna, Ravenna, , Italy
Centroricerche Cliniche Di Verona Srl, Verona, , Italy
Auckland City Hospital, Auckland, , New Zealand
North Shore Hospital, Takapuna, , New Zealand
Wellington Regional Hospital (Ccdhb), Wellington, , New Zealand
Hospital de La Santa Creu I Sant Pau, Barcelona, , Spain
Vall D Hebron Institute of Oncology Vhio, Barcelona, , Spain
Ico H Duran I Reynals, Barcelona, , Spain
Hospital Clinic de Barcelona, Barcelona, , Spain
Start Madrid Fundacion Jimenez Diaz, Madrid, , Spain
Clinica Universidad de Navarra Pamplona, Pamplona, , Spain
Hospital Universitario de Salamanca, Salamanca, , Spain
Hospital Universitario Marques de Valdecilla, Santander, , Spain
Oxford University Hospitals Nhs Foundation Trust, Oxford, , United Kingdom
Contact Details
Name: David Simpson
Affiliation: BeiGene
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
